PTGS2 and hepatocellular carcinoma: This demonstrates that SS-d exerts its anti-hepatoma effects by dose-dependently inhibiting the p-STAT3/C/EBPβ signaling pathway and significantly reducing the expression of cyclooxygenase (COX)-2.